KR20030088466A - 안과 국소 투여용 마크롤라이드계 약제 조성물 - Google Patents
안과 국소 투여용 마크롤라이드계 약제 조성물 Download PDFInfo
- Publication number
- KR20030088466A KR20030088466A KR10-2003-7012372A KR20037012372A KR20030088466A KR 20030088466 A KR20030088466 A KR 20030088466A KR 20037012372 A KR20037012372 A KR 20037012372A KR 20030088466 A KR20030088466 A KR 20030088466A
- Authority
- KR
- South Korea
- Prior art keywords
- azithromycin
- oil carrier
- solution
- oil
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Abstract
Description
경 과 시 간(시간) | 아지스로마이신] / 눈물 (㎍/g) |
0.5 | 8.85 |
1 | 4.53 |
2 | 2.45 |
4 | 1.68 |
8 | 0.87 |
24 | 0.91 |
경 과 시 간(시간) | 아지스로마이신/눈물 (㎍/g) |
72 | 2.53* |
96 | 2.98 |
120 | 5.61 |
144 | 2.14 |
Claims (11)
- 치료 활성 성분으로서 특히 아잘라이드류에서 선택된 용액으로 된 마크롤라이드계 항생 화합물을 오일 운반체 내에 포함하고 있는, 점안액 형태로 되어 있는 것을 특징으로 하는 국소 투여 방식의 전염성 안과질환 치료용 약제 조성물.
- 제1항에 있어서, 상기 오일 운반체는 생리학적으로 적합한 특성을 나타내고 지방산 트리글리세리드로 구성된 식물성 지방 오일인 것을 특징으로 하는 치료용 약제 조성물.
- 제1항 또는 제2항에 있어서, 상기 오일 운반체가, 평균길이의 직쇄를 갖는 포화탄화수소산의 카르복실산 트리글리세리드로 구성되고 이 지방산의 트리글리세리드는 5 내지 12 탄소원자를 갖는, 바람직하기로는, 카프릴산 및/또는 카프르산과 같이 8 내지 10 탄소원자를 갖는 분자인 것을 특징으로 하는 치료용 약제 조성물.
- 제1항 내지 제3항중 어느 한 항에 있어서, 상기 오일 운반체가 상온에서 최소 10 mPa.s 이상, 최대 100 mPa.s 이하의 점성, 보다 바람직하게는 10 내지 50 mPa.s 범위의 점성, 특히 바람직하게는 20 내지 40 mPa.s 범위의 점성을 나타내고, 밀도가 1에 유사한 값, 특히 바람직하게는 0.9 내지 1 범위의 밀도를 나타내는 것을 특징으로 하는 치료용 약제 조성물.
- 제1항 내지 제4항중 어느 한 항에 있어서, 상기 오일 운반체는 1 내지 2 범위의 굴절율, 보다 바람직하게는 1.3 내지 1.5 범위의 굴절률, 특히 바람직하게는 1.45의 굴절률을 나타내는 것을 특징으로 하는 치료용 약제 조성물.
- 제1항 내지 제5항중 어느 한 항에 있어서, 상기 치료용 약제가 1회 사용 목적의 단일용량 작은병에 담기는 것을 특징으로 하는 치료용 약제 조성물.
- 제1항 내지 제6항 중의 어느 한 항에 있어서, 상기 치료 활성 성분이 0.7 내지 2중량% 범위의 농도, 특히 바람직하게는, 1 내지 1.5중량% 범위의 농도를 갖는 아지스로마이신인 것을 특징으로 하는 치료약제 조성물.
- 마크롤라이드계 항생 화합물, 특히, 중간 길이 직쇄형 지방산 트리글리세리드로 구성된 식물성 오일 운반체에 함유된 용액 형태의 아지스로마이신과 같은 아잘라이드류 화합물을 사용하는 것을 특징으로 하는 안과질환 치료용 국소 투여 점안액 조성물의 제조방법
- 제8항에 있어서, 상기 치료용 조성물이 상온 조건, 경우에 따라서는 80℃ 이하의 온도로 약간 가열된 상태에서, 최대 0.2㎛와 같거나 그 이하의 다공성을 나타내는 필터막을 통해 필터여과식 멸균 처리되는 것을 특징으로 하는 점안액 조성물의 제조방법.
- 총중량 대비 1 내지 1.5중량% 범위의 농도를 나타내는 오일 운반체에 함유된 용액 형태의 아지스로마이신을 치료 활성 성분으로 포함하고, 상기 오일 운반체는 중간 길이 직쇄형의 포화 탄화수소 카르복실산, 특히, 카프릴산 및/또는 카프르산 트리글리세리드로 구성된 것을 특징으로 하는 전염성 안과질환 치료용 국소 투여 점안액 조성물.
- 국소 투여 전염성 안과질환 치료에 적합한 점안액 제조시 오일 운반체 내에 용액 형태로 포함되는 염기형 아지스로마이신의 용도.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR01/05114 | 2001-04-12 | ||
FR0105114A FR2823441B1 (fr) | 2001-04-12 | 2001-04-12 | Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation |
PCT/FR2002/001263 WO2002083178A1 (fr) | 2001-04-12 | 2002-04-11 | Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030088466A true KR20030088466A (ko) | 2003-11-19 |
KR100835002B1 KR100835002B1 (ko) | 2008-06-09 |
Family
ID=8862340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037012372A KR100835002B1 (ko) | 2001-04-12 | 2002-04-11 | 안과 국소 투여용 마크롤라이드계 약제 조성물 |
Country Status (31)
Country | Link |
---|---|
US (1) | US7064109B2 (ko) |
EP (1) | EP1377316B1 (ko) |
JP (2) | JP4558275B2 (ko) |
KR (1) | KR100835002B1 (ko) |
CN (1) | CN1496270B (ko) |
AR (1) | AR034033A1 (ko) |
AT (1) | ATE397460T1 (ko) |
BR (1) | BRPI0208367B8 (ko) |
CA (1) | CA2443728C (ko) |
CY (1) | CY1108302T1 (ko) |
CZ (1) | CZ300213B6 (ko) |
DE (1) | DE60226962D1 (ko) |
DK (1) | DK1377316T3 (ko) |
EA (1) | EA008088B1 (ko) |
EG (1) | EG23169A (ko) |
ES (1) | ES2307754T3 (ko) |
FR (1) | FR2823441B1 (ko) |
HK (1) | HK1065708A1 (ko) |
HR (1) | HRP20030907B1 (ko) |
HU (1) | HU230459B1 (ko) |
MA (1) | MA27005A1 (ko) |
MX (1) | MXPA03009349A (ko) |
OA (1) | OA12462A (ko) |
PA (1) | PA8543401A1 (ko) |
PE (1) | PE20021082A1 (ko) |
PL (1) | PL204403B1 (ko) |
PT (1) | PT1377316E (ko) |
SI (1) | SI1377316T1 (ko) |
TN (1) | TNSN03091A1 (ko) |
WO (1) | WO2002083178A1 (ko) |
ZA (1) | ZA200307718B (ko) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004017477D1 (de) * | 2004-11-09 | 2008-12-11 | Novagali Pharma Sa | Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential |
FR2884716B1 (fr) * | 2005-04-22 | 2009-08-21 | Thea Sa Lab | Utilisation de l'azithromycine pour la fabrication d'un medicament destine au traitement des infections oculaires |
WO2007074904A1 (ja) * | 2005-12-28 | 2007-07-05 | Wakamoto Pharmaceutical Co., Ltd. | 水性医薬組成物 |
WO2008106228A2 (en) * | 2007-02-28 | 2008-09-04 | Aciex Therapeutics, Inc. | Methods and compositions for normalizing meibomian gland secretions |
US20100158821A1 (en) * | 2008-12-22 | 2010-06-24 | Eastman Chemical Company | Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products |
CN101780105B (zh) * | 2009-01-20 | 2011-09-28 | 沈阳兴齐制药有限公司 | 小牛血去蛋白提取物的滴眼液 |
EP2228058A1 (en) | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionic oil-in-water emulsion containing prostaglandins and uses thereof |
US8106111B2 (en) * | 2009-05-15 | 2012-01-31 | Eastman Chemical Company | Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions |
EP2389939A1 (en) | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
EP2394636B1 (en) * | 2010-05-28 | 2014-03-19 | Novagali Pharma S.A. | Method for treating retinal conditions using an intraocular tamponade |
US9044508B2 (en) * | 2013-03-15 | 2015-06-02 | Insite Vision Corporation | Concentrated aqueous azalide formulations |
WO2018005830A1 (en) * | 2016-06-29 | 2018-01-04 | Otonomy, Inc. | Triglyceride otic formulations and uses thereof |
PT3266446T (pt) * | 2016-07-07 | 2019-01-30 | Salvat Lab Sa | Composição oftálmica compreendendo óleo de rícino e triglicérido de cadeia média |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1152644A (en) * | 1966-07-01 | 1969-05-21 | Abbott Lab | Stable Solutions of Erythromycin Free Base |
JPS6468328A (en) * | 1987-09-09 | 1989-03-14 | Suntory Ltd | Anticorneoulcerative |
JP2563336B2 (ja) * | 1987-06-01 | 1996-12-11 | エーザイ株式会社 | 角膜透過促進点眼剤 |
FR2746035B1 (fr) * | 1996-03-15 | 1998-06-12 | Microparticules de gel composite susceptibles d'etre utilisees comme vecteur(s) de principe(s) actif(s), l'un de leurs procedes de preparation et leurs applications | |
DE69825128T3 (de) * | 1997-12-02 | 2010-05-06 | Pfizer Products Inc., Groton | Verwendung von azithromycin zur topischen behandlung von augeninfektionen |
JP2000159659A (ja) * | 1998-11-30 | 2000-06-13 | Kazuo Tsubota | 眼科用人工涙液 |
US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
-
2001
- 2001-04-12 FR FR0105114A patent/FR2823441B1/fr not_active Expired - Lifetime
-
2002
- 2002-04-09 PA PA20028543401A patent/PA8543401A1/es unknown
- 2002-04-10 AR ARP020101319A patent/AR034033A1/es not_active Application Discontinuation
- 2002-04-10 EG EG20020380A patent/EG23169A/xx active
- 2002-04-11 CN CN02806447XA patent/CN1496270B/zh not_active Expired - Lifetime
- 2002-04-11 CA CA2443728A patent/CA2443728C/fr not_active Expired - Lifetime
- 2002-04-11 AT AT02732804T patent/ATE397460T1/de active
- 2002-04-11 EP EP02732804A patent/EP1377316B1/fr not_active Expired - Lifetime
- 2002-04-11 PL PL363538A patent/PL204403B1/pl unknown
- 2002-04-11 DE DE60226962T patent/DE60226962D1/de not_active Expired - Lifetime
- 2002-04-11 BR BRPI0208367A patent/BRPI0208367B8/pt not_active IP Right Cessation
- 2002-04-11 US US10/474,811 patent/US7064109B2/en not_active Expired - Lifetime
- 2002-04-11 PT PT02732804T patent/PT1377316E/pt unknown
- 2002-04-11 CZ CZ20032771A patent/CZ300213B6/cs not_active IP Right Cessation
- 2002-04-11 PE PE2002000306A patent/PE20021082A1/es not_active Application Discontinuation
- 2002-04-11 WO PCT/FR2002/001263 patent/WO2002083178A1/fr active IP Right Grant
- 2002-04-11 TN TNPCT/FR2002/001263A patent/TNSN03091A1/fr unknown
- 2002-04-11 HU HU0303864A patent/HU230459B1/hu unknown
- 2002-04-11 OA OA1200300246A patent/OA12462A/fr unknown
- 2002-04-11 EA EA200301108A patent/EA008088B1/ru not_active IP Right Cessation
- 2002-04-11 MX MXPA03009349A patent/MXPA03009349A/es active IP Right Grant
- 2002-04-11 DK DK02732804T patent/DK1377316T3/da active
- 2002-04-11 ES ES02732804T patent/ES2307754T3/es not_active Expired - Lifetime
- 2002-04-11 KR KR1020037012372A patent/KR100835002B1/ko active IP Right Grant
- 2002-04-11 SI SI200230723T patent/SI1377316T1/sl unknown
- 2002-04-11 JP JP2002580979A patent/JP4558275B2/ja not_active Expired - Lifetime
-
2003
- 2003-09-26 MA MA27325A patent/MA27005A1/fr unknown
- 2003-10-02 ZA ZA200307718A patent/ZA200307718B/en unknown
- 2003-11-10 HR HR20030907A patent/HRP20030907B1/xx not_active IP Right Cessation
-
2004
- 2004-11-01 HK HK04108553.8A patent/HK1065708A1/xx not_active IP Right Cessation
-
2008
- 2008-08-28 CY CY20081100927T patent/CY1108302T1/el unknown
-
2009
- 2009-10-08 JP JP2009234250A patent/JP5170780B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5170780B2 (ja) | 眼科における局所用のマクロライド系医薬品組成物 | |
DE69907664T2 (de) | Verfahren zur Herstellung von wässrigen Formulierungen für ophthalmische Verwendung | |
US8901131B2 (en) | Gatifloxacin-containing ophthalmic gel and preparation method thereof | |
HU204202B (en) | Process for producing new, local pharmaceutical compositions | |
KR101117861B1 (ko) | 포르시토사이드 주사제와 그 제조 방법 | |
KR20060131938A (ko) | 점탄성 조성물을 포함하는 신규한 유리-라디칼 제거제,사용 방법 및 패키지 | |
WO2014045296A2 (en) | Improved daptomycin injectable formulation | |
WO2014180356A1 (en) | A sustained releasing pharmaceutical composition | |
JP2008536908A (ja) | 目の感染症の治療薬の製造のためのアジスロマイシンの利用 | |
RU2082434C1 (ru) | Глазная мазь | |
RU2014050C1 (ru) | Офтальмологическое средство и способ его получения | |
WO2012090170A1 (en) | Products for ophtalmic use | |
GB2339691A (en) | Veterinary compositions comprising an anthelmintic agent, polyethylene glycol and glycerol formal | |
RU2146924C1 (ru) | Средство, стимулирующее процессы заживления гнойных ран | |
US20230057383A1 (en) | Composition and methods for prevention and treatment of vascular disorders, neurodegenerative disease and neuropathic disorders | |
RU2197246C2 (ru) | Глазной препарат и способ его получения | |
RU2007152C1 (ru) | Офтальмологическое средство и способ его получения | |
KR100455531B1 (ko) | 티클로피딘을 활성성분으로 함유하는 각막 혈관신생억제조성물과 그 제조방법 | |
RU2041707C1 (ru) | Способ профилактики и лечения риккетсиозного конъюнктиво-кератита крупного рогатого скота | |
BR102016015590A2 (pt) | Intravital implants of polygactic-coglicolic acid (plga) containing lupeol or derivatives applied to the treatment of eyelium diseases with angiogenic base as diabetic retinopathy | |
BR102016015590B1 (pt) | Implantes intravitreos de ácido polilático-co-glicólico (alga) contendo lupeol ou derivados aplicados ao tratamento de doenças oculares com base angiogênica como a retinopa tia diabética | |
CN106389358A (zh) | 减少过敏反应的注射用头孢哌酮钠舒巴坦钠的药物组合物 | |
RO128481A2 (ro) | Forme farmaceutice semisolide cu administrare rectală conţinând tenoxicam |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130429 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140424 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150504 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170421 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180420 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20190425 Year of fee payment: 12 |